---
title: "PRESERVE IRE trial demonstrates safety and efficacy in intermediate-risk prostate cancer"
date: "2025-07-23T14:50:09.000Z"
publishedDate: "23 juillet 2025"
summary: "AngioDynamics has today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife system to ablate prostate tissue in patients with intermediate-risk prostate cancer in the journal European Urology. The NanoKnife system is a leading non-thermal, radiation-free, ablation technology designed to treat prostate [&#8230;] The post PRESERVE IRE trial demonstrates safety and efficacy in intermediate-risk prostate cancer appeared first on Interventional News ."
importance: ""
sourceUrl: "https://interventionalnews.com/preserve-ire-trial-demonstrates-safety-and-efficacy-in-intermediate-risk-prostate-cancer/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2025-07-23-preserve-ire-trial-demonstrates-safety-and-efficacy-in-intermediate-risk-prostate-cancer"
imageUrl: "http://interventionalnews.com/wp-content/uploads/sites/13/2025/01/AngioDynamics-logo-766x512-1.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/preserve-ire-trial-demonstrates-safety-and-efficacy-in-intermediate-risk-prostate-cancer/"
---

![PRESERVE IRE trial demonstrates safety and efficacy in intermediate-risk prostate cancer](http://interventionalnews.com/wp-content/uploads/sites/13/2025/01/AngioDynamics-logo-766x512-1.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/preserve-ire-trial-demonstrates-safety-and-efficacy-in-intermediate-risk-prostate-cancer/*

## L’essentiel

AngioDynamics has today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife system to ablate prostate tissue in patients with intermediate-risk prostate cancer in the journal European Urology. The NanoKnife system is a leading non-thermal, radiation-free, ablation technology designed to treat prostate [&#8230;] The post PRESERVE IRE trial demonstrates safety and efficacy in intermediate-risk prostate cancer appeared first on Interventional News .

## Lien source

https://interventionalnews.com/preserve-ire-trial-demonstrates-safety-and-efficacy-in-intermediate-risk-prostate-cancer/
